Pınar CÖMERT, Murat ALBAYRAK, Hacer Berna AFACAN ÖZTÜRK, Abdulkerim YILDIZ, Çiğdem PALA, Senem MARAL, Osman ŞAHİN

Akut Myeloid Lösemi'de Konvansiyonel Risk Faktörleri Önemini Koruyor mu?

Amaç: Bu çalışmanın amacı, merkezimize başvuran akut myeloid lösemi (AML) hastalarının sağkalım verilerini incelemek ve sağkalımı etkileyen kolay ve hızlı elde edilebilir faktörleri belirlemektir. Gereç ve Yöntem: 2009-2018 yılları arasında merkezimize başvuran ve AML tanısı konulan 119 hasta retrospektif olarak incelendi. Demografik ve hastalık verileri incelenerek tedaviye yanıt oranları, genel ve hastalıksız sağkalım oranları hesaplandı. Cox-regresyon analizi ile sağkalımı etkileyen faktörler belirlendi. Bulgular: 9 yıllık çalışma süresi boyunca toplam 119 hasta çalışmaya dahil edildi. Hastaların 21'i sekonder AML ve 11'i akut promyelositer lösemi (AML-M3) idi. Ortalama takip süresi 12.43±15.63 ay olarak bulundu. Hastalarda genel sağkalım (OS) 9.20 ay, hastalıksız sağkalım (PFS) 7.23 ay olarak bulundu. Hastaların tanı anındaki yaşı ve lökosit sayısının hem OS hem de PFS üzerine olumsuz etkisi olduğu görüldü (p

Are the Conventional Risk Factors Still Valid for Acute Myeloid Leukemia Patients?

Objective: The aim of this study was to investigate the survival data of patients withacute myeloid leukemia (AML) and to determine the risk factors that can be easilyevaluated.Methods: A retrospective analysis was made of the AML patients admitted to ourcenter between 2009 and 2018. Demographic and disease data were analyzed andresponse rates, overall survival (OS) and progression-free survival (PFS) rates werecalculated. Factors affecting survival were determined using Cox-regression analysis.Results: A total of 119 patients were included in the study during the 9-year studyperiod. Of these, 21 patients had secondary AML and 11 had acute promyelocyticleukemia (AML-M3). The mean follow-up period was 12.43 ± 15.63 months. OS of allpatients was 9.20 months and PFS was 7.23 months. Age and leukocyte count at thetime of diagnosis were significantly found to have adverse effect on both OS and PFS (p

PDF

___

1. Dohner H, Estey EH, Amadori S, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
2. Siegel R, Naishadham D, Jemal A. Cancer statistics, CA: a cancer journal for clinicians. 2012;62(1):10-29.
3. Ferrara F, Schiffer CA. Acute myeloid leukaemia in adults. Lancet (London, England). 2013;381(9865):484- 95.
4. Padilha SL, Souza EJ, Matos MC, et al. Acute myeloid leukemia: survival analysis of patients at a university hospital of Parana. Revista brasileira de hematologia e hemoterapia. 2015;37(1):21-7.
5. Rollig C, Ehninger G. How I treat hyperleukocytosis in acute myeloid leukemia. Blood. 2015;125(21):3246- 52.
6. Grimwade D. The changing paradigm of prognostic factors in acute myeloid leukaemia. Best practice & research Clinical haematology. 2012;25(4):419-25.
7. Liersch R, Muller-Tidow C, Berdel WE, et al. Prognostic factors for acute myeloid leukaemia in adults-- biological significance and clinical use. British journal of haematology. 2014;165(1):17-38.
8. Duployez N, Willekens C, Marceau-Renaut A, et al. Prognosis and monitoring of core-binding factor acute myeloid leukemia: current and emerging factors. Expert review of hematology. 2015;8(1):43-56.
9. Stone RM. The difficult problem of acute myeloid leukemia in the older adult. CA: a cancer journal for clinicians. 2002;52(6):363-71.
10. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129(4):424-47.
11. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood. 2009;113(18):4179-87.
12. Medinger M, Lengerke C, Passweg J. Novel Prognostic and Therapeutic Mutations in Acute Myeloid Leukemia. Cancer genomics & proteomics. 2016;13(5):317-29.
13. Mamez AC, Raffoux E, Chevret S, et al. Pre-treatment with oral hydroxyurea prior to intensive chemotherapy improves early survival of patients with high hyperleukocytosis in acute myeloid leukemia. Leukemia & lymphoma. 2016;57(10):2281-8.
14. Kuo KH, Callum JL, Panzarella T, et al. A retrospective observational study of leucoreductive strategies to manage patients with acute myeloid leukaemia presenting with hyperleucocytosis. British journal of haematology. 2015;168(3):384-94.
15. Greenwood MJ, Seftel MD, Richardson C, et al. Leukocyte count as a predictor of death during remission induction in acute myeloid leukemia. Leukemia & lymphoma. 2006;47(7):1245-52.
16. Oberoi S, Lehrnbecher T, Phillips B, et al. Leukapheresis and low-dose chemotherapy do not reduce early mortality in acute myeloid leukemia hyperleukocytosis: a systematic review and meta-analysis. Leukemia research. 2014;38(4):460-8.
17. Delaunay J, Mazur G, Minden M, et al. Relationship between baseline white blood cell count and renal and hepatic function in older patients with acute myeloid leukemia. Leukemia research reports. 2014;3(1):17-20.
18. Medinger M, Passweg JR. Acute myeloid leukaemia genomics. British journal of haematology. 2017;179(4):530-42.
19. Zhao BB, Zhu Z, Xu PP, et al. [Prognostic analysis of non-cytogenetic factors in elderly adults with acute myeloid leukemia]. Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi. 2013;34(1):3-7.
20. Le Jeune C, Bertoli S, Elhamri M, et al. Initial absolute lymphocyte count as a prognostic factor for outcome in acute myeloid leukemia. Leukemia & lymphoma. 2014;55(4):855-62.
21. Gbadamosi B, Ezekwudo D, Bastola S, et al. Predictive and Prognostic Markers in Adults With Acute Myeloid Leukemia: A Single-Institution Experience. Clinical lymphoma, myeloma & leukemia. 2018;18(7):287-94.
22. Appelbaum FR, Kopecky KJ, Tallman MS, et al. The clinical spectrum of adult acute myeloid leukaemia associated with core binding factor translocations. British journal of haematology. 2006;135(2):165-73.
23. Schoch C, Kern W, Schnittger S, et al. The influence of age on prognosis of de novo acute myeloid leukemia differs according to cytogenetic subgroups. Haematologica. 2004;89(9):1082-90.

ISSN: 1309-3878
Yayın Aralığı: Yılda 3 Sayı
Başlangıç: 2009
Yayıncı: Düzce Üniversitesi Tıp Fakültesi Aile Hekimliği AD adına Yrd.Doç.Dr.Cemil Işık Sönmez